Search results for "cell carcinoma"

showing 10 items of 519 documents

Melatonin Targets Metabolism in Head and Neck Cancer Cells by Regulating Mitochondrial Structure and Function.

2021

This study was funded by grants from the Ministerio de Economia, Industria y Competitividad y por el Fondo de Desarrollo Regional FEDER, Spain nº SAF2013-49019, SAF2017-85903-P, and from the Consejería de Innovación, Ciencia y Empresa, Junta de Andalucía (P07- CTS- 03135, P10- CTS- 5784, and CTS- 101), Spain. J.F. and L.M. have FPU fellowships from the Ministerio de Educación Cultura y Deporte, Spain. C.R.S. was a schorlarship holder from the Plan Propio de Investigación of the University of Granada.

0301 basic medicine:Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Phosphorylation::Oxidative Phosphorylation [Medical Subject Headings]PhysiologyClinical BiochemistrymelatoninMitochondrionBiochemistryMelatonina:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]0302 clinical medicine:Anatomy::Cells::Cells Cultured::Cell Line [Medical Subject Headings]head and neck cancer cells:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance Neoplasm [Medical Subject Headings]MitophagyMitocondriasChemistryapoptosisglycolysisOXPHOSmitochondria030220 oncology & carcinogenesishormones hormone substitutes and hormone antagonistsmedicine.drug:Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Carbohydrate Metabolism::Glycolysis [Medical Subject Headings]Neoplasias de cabeza y cuello:Diseases::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms [Medical Subject Headings]:Chemicals and Drugs::Inorganic Chemicals::Free Radicals::Reactive Oxygen Species [Medical Subject Headings]Mitofagiafree radicalsOxidative phosphorylationArticleMelatonin03 medical and health sciencesmedicine:Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Growth Processes::Cell Proliferation [Medical Subject Headings]Molecular BiologyRadicales libresCell growth:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::DNA-Binding Proteins::Receptors Cytoplasmic and Nuclear::Receptors Melatonin [Medical Subject Headings]:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings]lcsh:RM1-950:Anatomy::Cells::Cellular Structures::Subcellular Fractions::Mitochondria [Medical Subject Headings]Cell Biologymedicine.diseaseHead and neck squamous-cell carcinoma:Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Death::Apoptosis [Medical Subject Headings]Glucólisis030104 developmental biologylcsh:Therapeutics. PharmacologymitophagyApoptosisCancer cellCancer research:Chemicals and Drugs::Hormones Hormone Substitutes and Hormone Antagonists::Hormones::Melatonin [Medical Subject Headings]
researchProduct

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced…

2019

Abstract Purpose: IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells (Treg). Navoximod is an investigational small-molecule inhibitor of IDO1. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of navoximod in combination with atezolizumab, a PD-L1 inhibitor, in patients with advanced cancer. Patients and Methods: The study consisted of a 3+3 dose-escalation stage (n = 66) and a tumor-specific expansion stage (n = 92). Navoximod was given orally every 12 hours continuously for 21 consecu…

0301 basic medicineAdultCancer ResearchIndoles[SDV]Life Sciences [q-bio][SDV.BC]Life Sciences [q-bio]/Cellular BiologyPharmacologyAntibodies Monoclonal HumanizedArticleB7-H1 Antigen03 medical and health sciences0302 clinical medicinePharmacokineticsAtezolizumabRenal cell carcinomaNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIndoleamine-Pyrrole 23-DioxygenaseNeoplasm MetastasisAgedNeoplasm StagingAged 80 and overBladder cancerbusiness.industryMelanomaImidazolesMiddle Agedmedicine.diseaseMagnetic Resonance Imaging3. Good health030104 developmental biologyTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisPharmacodynamicsPD-L1 inhibitorbusinessTomography X-Ray Computed
researchProduct

Metabolic Profile of Oral Squamous Carcinoma Cell Lines Relies on a Higher Demand of Lipid Metabolism in Metastatic Cells

2017

Tumor cells are subjected to a broad range of selective pressures. As a result of the imposed stress, subpopulations of surviving cells exhibit individual biochemical phenotypes that reflect metabolic reprograming. The present work aimed at investigating metabolic parameters of cells displaying increasing degrees of metastatic potential. The metabolites present in cell extracts fraction of tongue fibroblasts and of cell lines derived from human tongue squamous cell carcinoma lineages displaying increasing metastatic potential (SCC9 ZsG, LN1 and LN2) were analyzed by 1H NMR (nuclear magnetic resonance) spectroscopy. Living, intact cells were also examined by the non-invasive method of fluore…

0301 basic medicineCancer ResearchBioenergeticsOxidative phosphorylationlcsh:RC254-28203 medical and health sciences0302 clinical medicinemetastasismetabolic reprogrammingGlycolysisOriginal ResearchChemistryCatabolismLipid metabolismlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenscancer progressionmetabolomicsSquamous carcinomaCell biologyoral squamous cell carcinomanuclear magnetic resonance030104 developmental biologyOncologyCell culture030220 oncology & carcinogenesisNAD+ kinaseFrontiers in Oncology
researchProduct

Establishment and characterization of a highly immunogenic human renal carcinoma cell line.

2015

Renal cell carcinoma (RCC) is the most common kidney cancer, and accounts for ~3% of all adult malignancies. RCC has proven refractory to conventional treatment modalities but appears to be the only histological form that shows any consistent response to immunotherapeutic approaches. The development of a clinically effective vaccine remains a major strategic target for devising active specific immunotherapy in RCC. We aimed to identify a highly immunogenic antigenic format for immunotherapeutic approaches, so as to boost immune responses in RCC patients. We established and cloned an immunogenic cell line, RCC85#21 named Elthem, which was derived from a non-aggressive and non-metastatic clea…

0301 basic medicineCancer ResearchCellClone (cell biology)BiologyImmunophenotyping03 medical and health sciencesimmunogenic antigenic format0302 clinical medicineImmune systemAntigenAntigens NeoplasmCell Line TumormedicineCytotoxic T cellHumansElectrophoresis Gel Two-DimensionalCarcinoma Renal Cellrenal cancer cell lineSystems BiologyArticlesCell cycleMolecular biologyKidney Neoplasms030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisSpectrometry Mass Matrix-Assisted Laser Desorption-Ionizationcell proteomeClear cell carcinomaK562 CellsCD8International journal of oncology
researchProduct

AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression

2016

Accumulating evidences have shown the association between aberrantly expressed microRNAs (miRs) and cancer, where these small regulatory RNAs appear to dictate the cell fate by regulating all the main biological processes. We demonstrated the responsibility of the circuitry connecting the oncomiR-221&222 with the tumor suppressors miR-126&126∗ in melanoma development and progression. According to the inverse correlation between endogenous miR-221&222 and miR-126&126∗, respectively increasing or decreasing with malignancy, their enforced expression or silencing was sufficient for a reciprocal regulation. In line with the opposite roles of these miRs, protein analyses confirmed the reverse ex…

0301 basic medicineCancer ResearchCellular differentiationSettore MED/08 - Anatomia Patologicagrowth-factorCell fate determinationBiologyFatty Acid-Binding ProteinsBioinformaticsap-2 transcription factorlaw.inventioncutaneous melanoma03 medical and health sciencesMolecular Biology; Cancer Research; Genetics0302 clinical medicinelawTranscription (biology)Cell Line TumormicroRNAGeneticsmedicineHumansGene silencingMelanomaMolecular BiologyPsychological repressionsquamous-cell carcinoma; ap-2 transcription factor; cutaneous melanoma; growth-factor; metastatic melanoma; terminal fragment; cancer-cells; tumor-growth; mir-126; methylationMelanomaCell Differentiationsquamous-cell carcinomatumor-growthmedicine.diseaseMicroRNAscancer-cells030104 developmental biologyterminal fragmentmir-126030220 oncology & carcinogenesisDisease ProgressionCancer researchSuppressorOriginal Articlemethylationmetastatic melanomaOncogene
researchProduct

Knockdown of hnRNPK leads to increased DNA damage after irradiation and reduces survival of tumor cells.

2017

Radiotherapy is an important treatment option in the therapy of multiple tumor entities among them head and neck squamous cell carcinoma (HNSCC). However, the success of radiotherapy is limited by the development of radiation resistances. Heterogeneous nuclear ribonucleoprotein K (hnRNPK) is a cofactor of p53 and represents a potential target for radio sensitization of tumor cells. In this study, we analyzed the impact of hnRNPK on the DNA damage response after gamma irradiation. By yH2AX foci analysis, we found that hnRNPK knockdown increases DNA damage levels in irradiated cells. Tumor cells bearing a p53 mutation showed increased damage levels and delayed repair. Knockdown of hnRNPK appl…

0301 basic medicineCancer ResearchDNA damageCell Survivalmedicine.medical_treatmentmedicine.disease_causeRadiation ToleranceHeterogeneous-Nuclear Ribonucleoprotein KHistones03 medical and health sciences0302 clinical medicineCell Line TumormedicineCarcinomaGene Knockdown TechniquesHumansMutationGene knockdownChemistrySquamous Cell Carcinoma of Head and NeckStem CellsGeneral Medicinemedicine.diseaseHead and neck squamous-cell carcinomaRadiation therapy030104 developmental biologyCell cultureHead and Neck Neoplasms030220 oncology & carcinogenesisGene Knockdown TechniquesCancer researchCarcinoma Squamous CellTumor Suppressor Protein p53DNA DamageCarcinogenesis
researchProduct

Growth differentiation factor 15 as a radiation-induced marker in oral carcinoma increasing radiation resistance.

2015

Background Growth differentiation factor 15 (GDF15) is involved in tumor pathogenesis of oral squamous cell carcinoma (OSCC). The aim of this study was an investigation of the potential influence of GDF15 on radioresistance of OSCC cells in vitro. Methods Oral squamous cell carcinoma cell lines were irradiated with 0, 2, or 6 Gy, and GDF15 expression in the supernatant per survived cell colony was examined with ELISA. Non-irradiated and OSCC cell lines irradiated with 6 Gy were evaluated for GDF15 expression using immunofluorescent staining. For further investigation of GDF15 effects on radioresistance, a GDF15 knockdown model in a human OSCC cell line was established, and apoptotic activit…

0301 basic medicineCancer ResearchGrowth Differentiation Factor 15CellApoptosisEnzyme-Linked Immunosorbent AssayBiologymedicine.disease_causeReal-Time Polymerase Chain ReactionTransfectionPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineRadioresistanceCell Line TumormedicineCarcinomaBiomarkers TumorHumansRNA Small InterferingMouth neoplasmSquamous Cell Carcinoma of Head and Neckmedicine.diseaseMolecular biologyNeoplasm Proteinsstomatognathic diseases030104 developmental biologymedicine.anatomical_structureOtorhinolaryngologyApoptosisCell cultureTumor progressionHead and Neck Neoplasms030220 oncology & carcinogenesisCaspasesGene Knockdown TechniquesCarcinoma Squamous CellPeriodonticsMouth NeoplasmsOral SurgeryCarcinogenesisJournal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
researchProduct

Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis

2020

Although innovative therapeutic concepts have led to better treatment of advanced renal cell carcinoma (RCC), efficacy is still limited due to the tumor developing resistance to applied drugs. Artesunate (ART) has demonstrated anti-tumor effects in different tumor entities. This study was designed to investigate the impact of ART (1&ndash

0301 basic medicineCancer ResearchTraditional Chinese Medicine (TCM) growth inhibition ferroptosis reactive oxygen species (ROS)Cell cycle checkpointBiologyurologic and male genital diseasesreactive oxygen species (ROS)lcsh:RC254-282Articlegrowth inhibition03 medical and health scienceschemistry.chemical_compound0302 clinical medicinerenal cell carcinoma (RCC)medicineClonogenic assayCytotoxicityartesunate (ART)SunitinibTraditional Chinese Medicine (TCM)Cell cyclelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensferroptosissunitib resistance030104 developmental biologyOncologychemistryCell cultureApoptosis030220 oncology & carcinogenesisCancer researchGrowth inhibitionmedicine.drugCancers
researchProduct

Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

2019

Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC. Methods: The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic. Results: We performed an up-to-date critical review taking into account the…

0301 basic medicineCancer Researchmedicine.medical_specialtyAvelumabSkin NeoplasmsPrognosimedicine.medical_treatmentPembrolizumabImmune checkpoint inhibitorCochrane LibraryB7-H1 AntigenSettore MED/13 - EndocrinologiaAvelumab03 medical and health sciencesImmune checkpoint inhibitors0302 clinical medicineMerkel cell carcinomaNeuroendocrine tumoursNeuroendocrine tumourmedicineAnimalsHumansSkin NeoplasmIntensive care medicineMerkel cell carcinomabusiness.industryAnimalAntibodies MonoclonalGeneral MedicineImmunotherapymedicine.diseasePrognosisImmune checkpointBlockadeClinical trialCarcinoma Merkel Cell030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyTherapyAvelumab; Immune checkpoint inhibitors; Merkel cell carcinoma; Neuroendocrine tumours; Pembrolizumab; TherapybusinessPembrolizumabmedicine.drugHuman
researchProduct

Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors

2018

Abstract Background: PIK3CA, a gene that encodes the α-isoform of the catalytic subunit of Class I PI3K (PI3Kα), is frequently mutated or amplified in solid tumors. Taselisib is an oral, potent, selective inhibitor of Class I PI3Kα, γ, and δ isoforms with enhanced activity against PIK3CA-mutated cancer models. Preclinical and clinical data demonstrated that single-agent taselisib has activity in multiple PIK3CA-mutated tumor types. Methods: This open-label phase I study (Cohort X of PMT4979g; NCT01296555) enrolled patients (pts) with PIK3CA-mutated tumors who had progressed after, or failed to respond to, at least one prior treatment regimen and were not candidates for regimens known to pro…

0301 basic medicineCervical cancerCancer Researchmedicine.medical_specialtybusiness.industryEndometrial cancerNot Otherwise SpecifiedCancermedicine.diseaseGastroenterologyHead and neck squamous-cell carcinoma03 medical and health sciencesRegimen030104 developmental biologyOncologyTolerabilityResponse Evaluation Criteria in Solid TumorsInternal medicinemedicinebusinessCancer Research
researchProduct